CN109640995A - 用脂质体伊立替康治疗小细胞肺癌 - Google Patents

用脂质体伊立替康治疗小细胞肺癌 Download PDF

Info

Publication number
CN109640995A
CN109640995A CN201780042803.5A CN201780042803A CN109640995A CN 109640995 A CN109640995 A CN 109640995A CN 201780042803 A CN201780042803 A CN 201780042803A CN 109640995 A CN109640995 A CN 109640995A
Authority
CN
China
Prior art keywords
irinotecan
liposome
sclc
patient
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780042803.5A
Other languages
English (en)
Chinese (zh)
Inventor
B·阿迪维加亚
J·B·菲茨杰拉德
H·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of CN109640995A publication Critical patent/CN109640995A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780042803.5A 2016-05-18 2017-05-17 用脂质体伊立替康治疗小细胞肺癌 Pending CN109640995A (zh)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201662337961P 2016-05-18 2016-05-18
US62/337,961 2016-05-18
US201662345178P 2016-06-03 2016-06-03
US62/345,178 2016-06-03
US201662362735P 2016-07-15 2016-07-15
US62/362,735 2016-07-15
US201662370449P 2016-08-03 2016-08-03
US62/370,449 2016-08-03
US201662394870P 2016-09-15 2016-09-15
US62/394,870 2016-09-15
US201662414050P 2016-10-28 2016-10-28
US62/414,050 2016-10-28
US201662415821P 2016-11-01 2016-11-01
US62/415,821 2016-11-01
US201662422807P 2016-11-16 2016-11-16
US62/422,807 2016-11-16
US201662433925P 2016-12-14 2016-12-14
US62/433,925 2016-12-14
US201762455823P 2017-02-07 2017-02-07
US62/455,823 2017-02-07
US201762474661P 2017-03-22 2017-03-22
US62/474,661 2017-03-22
PCT/IB2017/000681 WO2017199093A1 (en) 2016-05-18 2017-05-17 Nanoliposomal irinotecan for use in treating small cell lung cancer

Publications (1)

Publication Number Publication Date
CN109640995A true CN109640995A (zh) 2019-04-16

Family

ID=59258274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780042803.5A Pending CN109640995A (zh) 2016-05-18 2017-05-17 用脂质体伊立替康治疗小细胞肺癌

Country Status (16)

Country Link
US (1) US20230000858A1 (enExample)
EP (1) EP3458059A1 (enExample)
JP (3) JP2019516693A (enExample)
KR (1) KR20190009319A (enExample)
CN (1) CN109640995A (enExample)
AU (1) AU2017267449A1 (enExample)
BR (1) BR112018072988A2 (enExample)
CA (1) CA3023743A1 (enExample)
IL (1) IL262656A (enExample)
MA (1) MA45046A (enExample)
MX (1) MX394766B (enExample)
PH (1) PH12018502422A1 (enExample)
SG (2) SG11201809788VA (enExample)
TW (1) TWI791437B (enExample)
UA (1) UA125646C2 (enExample)
WO (1) WO2017199093A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104717961A (zh) * 2012-06-13 2015-06-17 梅里麦克制药股份有限公司 使用含脂质体伊立替康的组合疗法治疗胰腺癌的方法
US20160058704A1 (en) * 2007-08-17 2016-03-03 Celator Pharmaceuticals Inc. Platinum drug formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2424792C2 (ru) * 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058704A1 (en) * 2007-08-17 2016-03-03 Celator Pharmaceuticals Inc. Platinum drug formulations
CN104717961A (zh) * 2012-06-13 2015-06-17 梅里麦克制药股份有限公司 使用含脂质体伊立替康的组合疗法治疗胰腺癌的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL C. CHAN等: "Abstract 4626: Evaluating the pharmacodynamics and pharmacokinetic effects of MM-398, a nanoliposomal irinotecan (nal-IRI) in subcutaneous xenograft tumor models of human squamous cell carcinoma and small cell lung cancers", 《CANCER RESEARCH》 *
MASAHIRO MORISE等: "Low-dose Irinotecan as a Second-line Chemotherapy for Recurrent Small Cell Lung Cancer", 《JAPANESE JOURNAL OF CLINICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
JP2019516693A (ja) 2019-06-20
IL262656A (en) 2018-12-31
SG11201809788VA (en) 2018-12-28
BR112018072988A2 (pt) 2019-04-09
UA125646C2 (uk) 2022-05-11
MX394766B (es) 2025-03-24
EP3458059A1 (en) 2019-03-27
JP2022010295A (ja) 2022-01-14
TW201740946A (zh) 2017-12-01
SG10201912407YA (en) 2020-02-27
JP2020117548A (ja) 2020-08-06
CA3023743A1 (en) 2017-11-23
TWI791437B (zh) 2023-02-11
MX2018013873A (es) 2019-02-14
US20230000858A1 (en) 2023-01-05
WO2017199093A1 (en) 2017-11-23
AU2017267449A1 (en) 2018-11-15
KR20190009319A (ko) 2019-01-28
MA45046A (fr) 2019-03-27
PH12018502422A1 (en) 2019-03-11

Similar Documents

Publication Publication Date Title
CN109640995A (zh) 用脂质体伊立替康治疗小细胞肺癌
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
US11318131B2 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2020073601A (ja) リポソーマルイリノテカンによる乳がんの治療
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
Lilenbaum et al. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study
TW201141472A (en) Method to treat small cell lung cancer
Wang et al. Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer
HK40005832A (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
US20200268703A1 (en) Medicine for treating advanced or recurrent cancer patient being non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable
CN104334192A (zh) 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
HK40040887A (en) Methods of treating cancer in pediatric patients
HK40010824A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2015000532A (es) Composicion anti-tumoral que comprende el compuesto 1- (6- { [6- (4-fluorofenil) [1,2,4] triazolo [4,3-b] piridazin-3-il] sulfanil} -1,3-benzotiazol-2-il) -3- (2-morfolin-4-iletil) urea.
Choy RADIATION THERAPY ONCOLOGY GROUP RTOG 0017
CN119818513A (zh) 治疗儿科患者的癌症的方法
Miyazaki et al. tor of tubulin polymerization. Ann Oncol 9 (Suppl 2) Abstr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005832

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40005832

Country of ref document: HK